Eloxx Pharmaceuticals (ELOX) vs Instil Bio (TIL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Eloxx Pharmaceuticals is the larger company by market cap ($43.7 million vs $35.5 million), about 1.2 times the size, while Instil Bio is growing revenue faster (+152.4% vs -100.0%).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ELOX | TIL |
|---|---|---|
| Share price | $10.69 | $5.23 |
| Market cap | $43.69M | $35.47M |
| 1-day change | -1.75% | -5.77% |
| YTD return | — | -52.45% |
| 1-year return | — | -60.20% |
| 5-year return | — | -98.72% |
| P/E ratio (TTM) | 5.63 | — |
| EPS (TTM) | $1.90 | $-3.09 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | $10.77M |
| Revenue growth (YoY) | -100.00% | +152.38% |
| Net income (latest FY) | $-6.00M | $-71.37M |
| Operating margin | — | -745.39% |
| Net margin | — | -662.75% |
| 52-week high | $23.40 | $12.92 |
| 52-week low | $8.20 | $5.14 |
| Distance from 52-week high | -54.32% | -59.51% |
| Analyst consensus | none | none |
| Avg. price target upside | +257.81% | +33.84% |
| Average volume | 28.48K | 42.02K |
| Shares outstanding | 4.09M | 6.78M |
| Employees | 10 | 17 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Instil Bio grew revenue faster in its latest fiscal year (+152.38% vs -100.00%).
About Eloxx Pharmaceuticals
ELOX stock →Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia. The company is developing exaluren, a eukaryotic ribosome-selective glycoside in a Phase 2 trial for the treatment of rare kidney diseases, including Alport syndrome with nonsense mutations, cystic fibrosis with nonsense mutations, and nephropathic cystinosis with nonsense mutations, as well as in a preclinical stage for the treatment of autosomal dominant polycystic kidney disease with nonsense mutations.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 10 employees
About Instil Bio
TIL stock →Instil Bio, Inc., a biopharmaceutical company, focuses on identifying and advancing therapeutic opportunities. It seeks to in-license or acquire and develop additional novel therapeutic candidates in diseases with significant unmet medical need.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 17 employees
ELOX vs TIL FAQ
Which is bigger, Eloxx Pharmaceuticals or Instil Bio?
Eloxx Pharmaceuticals (ELOX) is larger, with a market capitalization of $43.69M compared with $35.47M for Instil Bio (TIL).
Are Eloxx Pharmaceuticals and Instil Bio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.